{"id":"asct-conditioning","safety":{"commonSideEffects":[{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hepatic toxicity"},{"rate":null,"effect":"Renal toxicity"},{"rate":null,"effect":"Secondary malignancy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ASCT (autologous stem cell transplant) conditioning typically involves high-dose chemotherapy agents, often including alkylating agents and/or total body irradiation, designed to ablate the patient's bone marrow and eliminate disease burden. This creates an immunologic and physical space for reinfusion of the patient's own previously harvested hematopoietic stem cells, which then reconstitute the bone marrow and immune system.","oneSentence":"ASCT conditioning is a high-dose chemotherapy regimen used to prepare the bone marrow for autologous stem cell transplantation by eliminating malignant cells and creating space for donor stem cells to engraft.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:39.064Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Lymphoma (Hodgkin and non-Hodgkin)"},{"name":"Leukemia"},{"name":"Other hematologic malignancies"}]},"trialDetails":[{"nctId":"NCT07481669","phase":"PHASE2","title":"ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"Lymphoma Patients With High-risk of Central Nervous System Relapse","enrollment":45},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT04923893","phase":"PHASE3","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-19","conditions":"Multiple Myeloma","enrollment":743},{"nctId":"NCT02844361","phase":"PHASE4","title":"Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-05","conditions":"Waldenström Macroglobulinemia","enrollment":70},{"nctId":"NCT02896582","phase":"PHASE2","title":"Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2016-11-29","conditions":"Mantle Cell Lymphoma","enrollment":86},{"nctId":"NCT02441686","phase":"PHASE2","title":"Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT03030261","phase":"PHASE2","title":"Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-11-22","conditions":"Multiple Myeloma in Relapse","enrollment":25},{"nctId":"NCT03346135","phase":"PHASE2","title":"Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-07-17","conditions":"Plasma Cell Myeloma, Secondary Amyloidosis","enrollment":31},{"nctId":"NCT03352765","phase":"PHASE1","title":"A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-11-20","conditions":"Lymphoma","enrollment":28},{"nctId":"NCT07236151","phase":"PHASE2","title":"Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-02-24","conditions":"Large B-cell Lymphoma, CAR T Cell Therapy, Auto Stem Cell Transplant","enrollment":23},{"nctId":"NCT06687772","phase":"PHASE2","title":"CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-01-16","conditions":"Diffuse Large B Cell Lymphoma","enrollment":36},{"nctId":"NCT05632380","phase":"PHASE1, PHASE2","title":"ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-07-14","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT07106710","phase":"PHASE2","title":"ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-10","conditions":"Multiple Myeloma, Newly Diagnosed","enrollment":30},{"nctId":"NCT07106684","phase":"PHASE2","title":"ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-10","conditions":"Multiple Myeloma, Plasma Cell Leukemia","enrollment":20},{"nctId":"NCT06793449","phase":"PHASE2","title":"BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-02-05","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT02278796","phase":"PHASE2","title":"A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2015-04","conditions":"Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell","enrollment":108},{"nctId":"NCT07072221","phase":"NA","title":"Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-11-01","conditions":"Peripheral T-cell Lymphoma","enrollment":40},{"nctId":"NCT07059741","phase":"NA","title":"Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-12-10","conditions":"Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)","enrollment":20},{"nctId":"NCT02329080","phase":"PHASE2","title":"New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2014-12","conditions":"Diffuse Large B-cell Lymphoma","enrollment":79},{"nctId":"NCT03713580","phase":"PHASE1","title":"Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2019-03-12","conditions":"Non-hodgkin Lymphoma","enrollment":25},{"nctId":"NCT06377540","phase":"PHASE2","title":"MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-12-04","conditions":"Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma","enrollment":28},{"nctId":"NCT06996132","phase":"PHASE2","title":"Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-05-09","conditions":"Relapsed or Refractory Aggressive B-cell Lymphoma","enrollment":25},{"nctId":"NCT07014943","phase":"PHASE2","title":"High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2022-01-01","conditions":"Primary Central Nervous System Lymphoma (PCNSL)","enrollment":34},{"nctId":"NCT01054196","phase":"PHASE1, PHASE2","title":"Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2010-08","conditions":"Multiple Myeloma","enrollment":52},{"nctId":"NCT06913192","phase":"PHASE1","title":"Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Xuzhou Medical University","startDate":"2025-04-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT03187223","phase":"PHASE2","title":"Bendamustine and Melphalan in Myeloma","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-07-20","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT02315716","phase":"PHASE2","title":"Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2015-06-16","conditions":"Multiple Myeloma","enrollment":281},{"nctId":"NCT05221645","phase":"PHASE2","title":"Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southampton","startDate":"2022-06-27","conditions":"Diffuse Large B Cell Lymphoma","enrollment":65},{"nctId":"NCT02043847","phase":"PHASE1","title":"TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2014-01-14","conditions":"Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment","enrollment":12},{"nctId":"NCT06646211","phase":"PHASE2","title":"High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-01-01","conditions":"Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL)","enrollment":30},{"nctId":"NCT05636787","phase":"PHASE2","title":"Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-06-06","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT02295722","phase":"PHASE1, PHASE2","title":"GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2015-04","conditions":"Hodgkin's Lymphoma - Relapsed/Refractory, Non-Hodgkin's Lymphoma - Aggressive, Follicular Lymphoma","enrollment":100},{"nctId":"NCT03217643","phase":"PHASE2","title":"CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.","status":"COMPLETED","sponsor":"Imagine Institute","startDate":"2018-02-07","conditions":"Enteropathy Associated T-cell Lymphoma","enrollment":14},{"nctId":"NCT04685525","phase":"NA","title":"Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-04-01","conditions":"Autologous Transplant, Myeloma","enrollment":""},{"nctId":"NCT06381830","phase":"PHASE2","title":"Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-01-01","conditions":"Lymphoma, B-Cell, Autologous Stem Cell Transplantation","enrollment":64},{"nctId":"NCT06376214","phase":"NA","title":"Daratumumab for Patients With Light Chain Amyloidosis","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2023-01-01","conditions":"Light Chain (AL) Amyloidosis","enrollment":100},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT01827605","phase":"PHASE3","title":"A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-01","conditions":"Relapsed Follicular Lymphoma","enrollment":159},{"nctId":"NCT03072771","phase":"PHASE1","title":"Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-08-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":14},{"nctId":"NCT04491370","phase":"PHASE1, PHASE2","title":"Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"New York Medical College","startDate":"2021-08-01","conditions":"B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":20},{"nctId":"NCT00571493","phase":"PHASE1, PHASE2","title":"VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-04-14","conditions":"Non-hodgkin's Lymphoma, Mantle Cell Lymphoma","enrollment":42},{"nctId":"NCT05444712","phase":"NA","title":"Transplantation After Complete Response In Patients With T-cell Lymphoma","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2022-08-01","conditions":"Peripheral T Cell Lymphoma","enrollment":204},{"nctId":"NCT05855122","phase":"PHASE4","title":"Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-04-17","conditions":"Multiple Myeloma","enrollment":48},{"nctId":"NCT00566098","phase":"PHASE1, PHASE2","title":"Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-11","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":26},{"nctId":"NCT05831865","phase":"","title":"Frontline of ASCT in High-risk DLBCL","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-05-03","conditions":"Diffuse Large B Cell Lymphoma","enrollment":175},{"nctId":"NCT05814718","phase":"NA","title":"Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-04-15","conditions":"Autologous Stem Cell Transplantation, Conditioning","enrollment":122},{"nctId":"NCT05228249","phase":"PHASE1","title":"Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-04","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","enrollment":""},{"nctId":"NCT05681403","phase":"NA","title":"Clinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-01-15","conditions":"Lymphoma, Autologous Hematopoietic Stem Cell Transplantation","enrollment":53},{"nctId":"NCT05558319","phase":"PHASE3","title":"NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2022-10","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":480},{"nctId":"NCT01702831","phase":"PHASE2","title":"Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2013-10-01","conditions":"Multiple Myeloma","enrollment":78},{"nctId":"NCT03645824","phase":"PHASE2","title":"Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2018-06-04","conditions":"Myelofibrosis","enrollment":61},{"nctId":"NCT01516593","phase":"PHASE2","title":"Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma","status":"COMPLETED","sponsor":"Andres J. M. Ferreri","startDate":"2011-11","conditions":"HIV, Burkitt's Lymphoma","enrollment":19},{"nctId":"NCT05398224","phase":"PHASE2","title":"R-MTX-zanbrutinib in Secondary CNS Lymphoma","status":"UNKNOWN","sponsor":"Peking University","startDate":"2021-02-26","conditions":"Secondary Central Nervous System Lymphoma","enrollment":45},{"nctId":"NCT04526223","phase":"NA","title":"Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation","status":"UNKNOWN","sponsor":"xuna","startDate":"2017-04-20","conditions":"Time of Hematopoietic Reconstruction","enrollment":30},{"nctId":"NCT04760184","phase":"","title":"Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-04-01","conditions":"Covid19, Myeloma Multiple, Malignant Lymphoma","enrollment":20},{"nctId":"NCT05137886","phase":"PHASE2","title":"PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-01","conditions":"Hodgkin Lymphoma, Adult, Relapse, Refractory Hodgkin Lymphoma","enrollment":47},{"nctId":"NCT04918511","phase":"PHASE1","title":"A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma","status":"WITHDRAWN","sponsor":"Oncopeptides AB","startDate":"2021-05-27","conditions":"Relapse Multiple Myeloma, Multiple Myeloma","enrollment":""},{"nctId":"NCT05054478","phase":"PHASE2","title":"Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-10","conditions":"Plasma Cell Leukemia","enrollment":29},{"nctId":"NCT04736914","phase":"PHASE2","title":"Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-01-31","conditions":"Mantle Cell Lymphoma","enrollment":47},{"nctId":"NCT03687125","phase":"PHASE1, PHASE2","title":"Tinostamustine Conditioning and Autologous Stem Cell","status":"TERMINATED","sponsor":"Mundipharma-EDO GmbH","startDate":"2018-10-15","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma With Failed Remission","enrollment":6},{"nctId":"NCT01045460","phase":"PHASE2","title":"Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-01-15","conditions":"Multiple Myeloma","enrollment":36},{"nctId":"NCT02439476","phase":"","title":"Non-interventional Study on Salvage Auto in Relapsed Myeloma","status":"COMPLETED","sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","startDate":"2016-08-08","conditions":"Relapsed Multiple Myeloma","enrollment":23},{"nctId":"NCT04127721","phase":"PHASE2","title":"Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-09-22","conditions":"Allogeneic Stem Cell Transplant Recipient, Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":""},{"nctId":"NCT02544425","phase":"PHASE2","title":"VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2016-02-21","conditions":"Extranodal NK-T-Cell Lymphoma","enrollment":27},{"nctId":"NCT01660633","phase":"PHASE2","title":"Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2012-12","conditions":"Multiple Myeloma","enrollment":61},{"nctId":"NCT00857389","phase":"PHASE2","title":"Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03-02","conditions":"Stem Cell Transplantation, Leukemia, Lymphoma","enrollment":60},{"nctId":"NCT00992446","phase":"PHASE2","title":"Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-09-02","conditions":"Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":27},{"nctId":"NCT00925782","phase":"PHASE2","title":"PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2010-01","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT00916058","phase":"PHASE1, PHASE2","title":"Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2009-04-23","conditions":"Multiple Myeloma","enrollment":57},{"nctId":"NCT00880815","phase":"PHASE1","title":"Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-02-17","conditions":"CD20 Positive, Chronic Lymphocytic Leukemia, Follicular Lymphoma","enrollment":60},{"nctId":"NCT00520130","phase":"PHASE1, PHASE2","title":"Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-10-30","conditions":"Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease","enrollment":92},{"nctId":"NCT03794167","phase":"PHASE2","title":"BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2012-06-01","conditions":"Non-hodgkin Lymphoma","enrollment":75},{"nctId":"NCT03562169","phase":"PHASE3","title":"The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)","status":"RECRUITING","sponsor":"University of Leeds","startDate":"2017-03-20","conditions":"Multiple Myeloma","enrollment":406},{"nctId":"NCT02858258","phase":"PHASE3","title":"ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Prof. Dr. M. Dreyling (co-chairman)","startDate":"2016-07","conditions":"Mantle Cell Lymphoma","enrollment":870},{"nctId":"NCT03100877","phase":"PHASE1, PHASE2","title":"Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2018-01","conditions":"Plasma Cell Leukemia in Remission, Plasma Cell Myeloma","enrollment":""},{"nctId":"NCT00642395","phase":"PHASE2","title":"Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2007-07","conditions":"Multiple Myeloma","enrollment":61},{"nctId":"NCT02084563","phase":"PHASE2","title":"Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2012-10","conditions":"Acute Myeloid Leukemia, Myeloproliferative Neoplasms, Myelodysplastic Syndromes","enrollment":455},{"nctId":"NCT02469974","phase":"NA","title":"Ruxolitinib in Combination With Autotransplant","status":"WITHDRAWN","sponsor":"Marina Kremyanskaya","startDate":"2015-05","conditions":"Myelofibrosis, MF","enrollment":""},{"nctId":"NCT02836639","phase":"PHASE2","title":"BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2016-02","conditions":"Lymphoma, Non-Hodgkin","enrollment":20},{"nctId":"NCT00892346","phase":"PHASE3","title":"Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma","status":"SUSPENDED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-05","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT01296256","phase":"PHASE2","title":"Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2011-05","conditions":"Bendamustine, Conditioning Therapy, Autologous Stem Cell Transplant","enrollment":60},{"nctId":"NCT00907582","phase":"PHASE2","title":"ASCT for Relapsed APL After Molecular Remission","status":"TERMINATED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-06","conditions":"Acute Promyelocytic Leukemia, Relapse","enrollment":5},{"nctId":"NCT01178645","phase":"PHASE2","title":"Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2010-07","conditions":"Non-Hodgkin Lymphoma","enrollment":42},{"nctId":"NCT01178658","phase":"PHASE2","title":"Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2010-07","conditions":"Non-Hodgkin Lymphoma","enrollment":42},{"nctId":"NCT00429026","phase":"PHASE2","title":"Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-01","conditions":"Renal Cell Cancer","enrollment":40},{"nctId":"NCT00525876","phase":"NA","title":"Non-Myeloablative Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-01","conditions":"Lymphoma","enrollment":49},{"nctId":"NCT01063439","phase":"PHASE2","title":"BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)","status":"UNKNOWN","sponsor":"Inje University","startDate":"2010-01","conditions":"Non Hodgkin's Lymphoma","enrollment":42},{"nctId":"NCT00946374","phase":"PHASE2","title":"Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2004-07","conditions":"Mantle-Cell Lymphoma","enrollment":20},{"nctId":"NCT00804947","phase":"PHASE2","title":"Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen","status":"UNKNOWN","sponsor":"Fundacion Para La Investigacion Hospital La Fe","startDate":"2005-09","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT00742300","phase":"PHASE1, PHASE2","title":"Autologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune Diseases","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"1998-01","conditions":"Autoimmune Diseases","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["THAM or BEAM"],"phase":"phase_3","status":"active","brandName":"ASCT conditioning","genericName":"ASCT conditioning","companyName":"Prof. Dr. M. Dreyling (co-chairman)","companyId":"prof-dr-m-dreyling-co-chairman","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASCT conditioning is a high-dose chemotherapy regimen used to prepare the bone marrow for autologous stem cell transplantation by eliminating malignant cells and creating space for donor stem cells to engraft. Used for Multiple myeloma, Lymphoma (Hodgkin and non-Hodgkin), Leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}